Announcement PDF RNS Number : 2342Y Genedrive PLC 29 December 2023 genedrive plc ("genedrive" or the "Company") Result of AGM genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces that at the Annual General Meeting, held today, all resolutions proposed were duly passed. For information, details of the proxy voting are shown below: Resolution 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Votes For Votes For (as % of votes cast) 9,120,276 8,958,874 8,949,212 8,958,212 7,803,515 9,075,202 8,983,550 9,061,602 9,085,116 8,962,881 7,805,054 8,968,751 8,962,881 8,960,351 98.8% 97.0% 97.3% 97.4% 97.1% 98.4% 97.5% 98.3% 98.6% 96.1% 83.7% 96.2% 96.1% 96.1% Votes Against 113,243 274,645 243,769 234,769 234,769 143,117 234,769 156,717 126,403 364,153 1,519,780 355,723 364,153 364,483 Votes Against (as % of votes cast) Vote Withheld 1.2% 3.0% 2.7% 2.6% 2.9% 1.6% 2.5% 1.7% 1.4% 3.9% 16.3% 3.8% 3.9% 3.9% 199,069 199,069 239,607 239,607 1,394,304 214,269 214,269 214,269 221,069 105,554 107,754 108,114 105,554 107,754 The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the Company's website (www.genedriveplc.com). For further details please contact: genedrive plc James Cheek: CEO / Russ Shaw: CFO +44 (0)161 989 0245 Peel Hunt LLP (Nominated Adviser and Broker) James Steel / Patrick Birkholm +44 (0)20 7418 8900 Walbrook PR Ltd (Media & Investor Relations) Anna Dunphy +44 (0)20 7933 8780 or genedrive@walbrookpr.com +44 (0)7876 741 001 About genedrive plc (http://www.genedriveplc.com) genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need pharmacogenetic platform for the diagnosis of genetic variations. This helps clinicians to quickly access key genetic information that will help them make the right choices over the right medicine or dosage to use for an effective treatment. Based in the UK, the Company is at the forefront of work on Point of Care pharmacogenetics. Pharmacogenetics looks at how your genetics impacts a medicines ability to work for you. Therefore, by using pharmacogenetics, medicines can be made safer and more effective. The Company has launched its flagship product, the Genedrive® MT-RNR1 ID Kit, which is a single-use disposable cartridge which circumvents the requirement for cold chain logistics by providing temperature stable reagent test kits for use on their proprietary test platform. This test allows clinicians to make a decision on antibiotic use within 26 minutes, ensuring vital care is delivered with no negative impact on the patient pathway. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END RAGBBBDDXSDDGXC